Serina Therapeutics, Inc. Proceeds from Sale of Equity Method Investments
Serina Therapeutics, Inc. (SER) reported Proceeds from Sale of Equity Method Investments of $466.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2023-03-31
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2021-12-31 was $0.00.
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2021-09-30 was $0.00.
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2021-06-30 was $0.00.
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2021-03-31 was $466.00K.
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2021 was $466.00K.
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2019 was $354.00K, a 88.99% decline from fiscal 2018.
- Serina Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2018 was $3.21M.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $466.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $466.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $466.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $466.00K 10-Q · filed 2022-05-13 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $77.00K derived: sum of 2 quarters · filed 2021-03-31 | $354.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $354.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $277.00K 10-Q · filed 2020-08-14 | |||
| 2018-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | $0.00 derived: sum of 2 quarters · filed 2020-03-31 | $0.00 derived: sum of 3 quarters · filed 2020-03-31 | $3.21M 10-K/A · filed 2020-03-31 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $3.21M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $3.21M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $3.21M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |